

8 July 2026

GRANT OF PATENTS BY THE US PATENT OFFICE

- **PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available**
- **The Company today announces that the US Patent Office has granted composition of matter patents covering PYC's RNA therapies across all three clinical-stage drug candidates¹**

PERTH, Australia and SAN FRANCISCO, California – 8 July 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

The Company currently has three clinical-stage drug development programs including drug candidates that address the underlying cause of:

- Polycystic Kidney Disease (known as PYC-003);
- Autosomal Dominant Optic Atrophy (known as PYC-001); and
- Retinitis Pigmentosa Type 11 (known as VP-001).

PYC today announces that the US Patent Office has granted composition of matter claims covering all three drug candidates and extending the patent life for:

- PYC-003 through to 13 June 2044;
- PYC-001 through to 10 April 2043; and
- VP-001 through to 17 May 2043.

The patent claims for the Company's Phelan-McDermid Syndrome drug candidate (known as PYC-002) are yet to be examined.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development².

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

¹ Patent claims supporting the Company's Phelan-McDermid Syndrome program are yet to be examined.

² Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.20222232>

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

CONTACT US

Investor relations and media contact

investor@pyctx.com

